LSTA-12(일본에서는 Honedra, CLBS12라고도 함)는 CLI와 버거씨병의 심각한 부작용을 예방하기 위한 실험적 재생의료로, CD34 세포치료제이며, 한 번의 치료로 대상 사지에 20회 근육주사하는 것을 목적으로 합니다. 치료합니다.
CD34 세포는 혈관의 발달과 회복을 촉진하는 줄기세포를 찾아내는 과정에서 발견되었습니다. 인체의 모든 조직은 시간이 지남에 따라 세포가 교체되어 기능을 유지하는데, CD34 세포를 투여하면 새로운 미세혈관의 발달과 형성을 촉진하여 환부에 대한 혈류량을 증가시킵니다. 현재까지 발견된 다른 토종 세포 중 이와 같은 능력을 가진 세포는 없습니다.
초기 임상 반응은 좋은 치료 효과와 안전성 프로파일과 일치하며, 일본 및 기타 지역에서 이미 발표된 CD34 세포 치료 임상시험과 일치합니다.
Caladrius의 독자적인 CD34 세포 치료 기술은 허혈로 인한 질병 및 질환을 치료할 수 있는 치료 제품 후보물질 개발로 이어지고 있습니다. 허혈은 건강한 조직에 산소를 포함한 혈액 공급이 제한되어 발생하는 것으로, 칼라드리우스는 관상동맥 미세혈관질환(CMD), 중증 허혈성 하지(CLI), 당뇨병성 신장질환(DKD), 비선택적 난치성 협심증(NORDA) 등 허혈성 손상으로 인한 여러 질환을 치료할 수 있는 CD34 세포 치료제를 개발하고 있습니다. 유발되는 여러 병태생리를 CD34 세포 기술을 통해 개선할 수 있을 것으로 기대하고 있습니다.
일본의 말초동맥 질환(PAD)용 LSTA-12에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.
"LSTA-12 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about LSTA-12 for Peripheral Artery Disease (PAD) in Japan. A detailed picture of the LSTA-12 for PAD in Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the LSTA-12 for PAD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LSTA-12 market forecast analysis for PAD in Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PAD.
LSTA-12 (also known as Honedra and CLBS12 in Japan) is an experimental regenerative medicine to prevent the serious adverse consequences of CLI and Buerger's disease by improving blood flow in the affected limb. It is CD34+ cell therapy intended to administer by Intramuscular route, 20 injections in the target limb in a single treatment.
The CD34+ cell was discovered due to the deliberate search for a stem cell capable of stimulating blood vessels' development and/or repair. All tissues in the human body maintain their function by replacing cells over time. By administering CD34+ cells, the company promotes the development and formation of new microvasculature, thereby increasing blood flow to the impacted area. No other native cell discovered to date has demonstrated this same capability.
The initial clinical responses are consistent with a positive therapeutic effect and safety profile and with previously published clinical trials of CD34+ cell therapy in Japan and elsewhere.
Caladrius' proprietary CD34+ cell therapy technology has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Caladrius believes that several conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology, including but not limited to coronary microvascular dysfunction (CMD), critical limb ischemia (CLI), diabetic kidney disease (DKD), and no-option refractory disabling angina (NORDA).
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
LSTA-12 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of LSTA-12 for Peripheral Artery Disease (PAD) in Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of LSTA-12 for PAD covering trial interventions, trial conditions, trial status, start and completion dates.